While the general population regained a certain level of normalcy with the end of the global
health emergency, the risk of contracting COVID-19 with a severe outcome is still a major …

Approximately 3% of US adults are immunocompromised and less capable of fighting
infections such as SARS-CoV-2 (the causative agent of COVID-19). Individuals may be …

The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

Introduction Immunocompromised individuals have been shown to mount a reduced
response to vaccination, resulting in reduced vaccine effectiveness in this cohort. Therefore …

Population immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has increased during the pandemic because of vaccination campaigns and …

The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Objectives Immunocompromised patients were excluded from COVID-19 vaccine clinical
trials. The objectives of the study were to measure antibody responses, levels, and …

Introduction While it is established that vaccination reduces risk of hospitalization, there is
conflicting data on whether it improves outcome among hospitalized COVID-19 patients …

Simple Summary With the current coronavirus disease 2019 (COVID-19) crisis, humans
have developed new habits and adapted to a novel socioeconomic reality. Indeed …

Background Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2;
COVID-19) pandemic has been unprecedented and affected daily activities at all levels …